What question did this study set out to answer?

To determine the cellular mechanism through which daclizumab, an antibody targeting the IL-2Ralpha chain, suppresses neuroinflammation in multiple sclerosis.

April 3, 2006Proceedings of the National Academy of SciencesOpen Access

Regulatory CD56 bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis

View Full Paper

Ask AI

Bookmark

Authors

BBBibiana BielekovaNational Institute of Allergy and Infectious Diseases MCMarta CatálfamoGeorgetown University SRSusan Reichert-ScrivnerTripler Army Medical Center

Discussion

Member takes

Implication

Mechanistic study reveals CD56bright natural killer cell expansion drives T cell reduction during daclizumab therapy in multiple sclerosis, suggesting a contact-dependent immunoregulatory pathway.

Key Points

To determine the cellular mechanism through which daclizumab, an antibody targeting the IL-2Ralpha chain, suppresses neuroinflammation in multiple sclerosis.
Monitored circulating CD4(+) and CD8(+) T cells and CD56(bright) natural killer cells in multiple sclerosis patients receiving daclizumab therapy.
Evaluated the impact of natural killer cells on activated T cell survival in peripheral blood mononuclear cell cultures in vitro.
Daclizumab produced only mild direct functional inhibition of CD4(+) T cells, but triggered marked expansion of CD56(bright) natural killer cells and a gradual decline in circulating CD4(+) and CD8(+) T cells in vivo.
CD56(bright) natural killer cell expansion correlated strongly with treatment response and with T cell contraction in vivo, while in vitro assays demonstrated that natural killer cells suppress activated T cell survival through a contact-dependent mechanism.

Cite This Study

Bielekova et al. (2006) studied this question.

synapsesocial.com/papers/6a8303d0162ea9d73e98fccc https://doi.org/10.1073/pnas.0601335103

View Full Paper

Ask AI

Bookmark

Implication

Mechanistic study reveals CD56bright natural killer cell expansion drives T cell reduction during daclizumab therapy in multiple sclerosis, suggesting a contact-dependent immunoregulatory pathway.

Regulatory CD56 bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Regulatory CD56 bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider